Literature DB >> 12043885

Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus.

W Füreder1, U Firbas, J L Nichol, J Pistillo, S Winkler, H Hiesberger, W R Sperr, J Smolen, G Schett.   

Abstract

Thrombocytopenia is a common phenomenon in patients suffering from systemic lupus erythematosus (SLE). The cause of thrombocytopenia in SLE, however, is poorly understood. In this study, 100 patients with SLE were evaluated for serum thrombopoietin levels, anti-thrombopoietin antibodies and routine laboratory parameters such as peripheral blood counts, parameters of blood chemistry and immunologic parameters of SLE. The median platelet count of SLE patients was 230 g/l and 19 were thrombocytopenic (range 8-148 g/l). Thrombopoietin levels in SLE patients were found to be significantly higher than in healthy controls (n = 96; median, 117 pg/ml vs 64 pg/ml, P < 0.01). When excluding thrombocytopenic SLE patients, thrombopoietin levels in SLE were still above controls (111 pg/ml, P < 0.01). The thrombopoietin levels were correlated to erythrocyte sedimentation rate and ECLAM score of disease activity, and inversely correlated to complement factor C4, but not to the platelet count. Anti-thrombopoietin antibody reactivity was found in 23% of SLE patients. Interestingly, these patients had lower platelet counts than SLE patients without anti-thrombopoietin antibodies (median 174 g/l and 253 g/l, respectively, P < 0.01), but thrombopoietin levels were not significantly different. Taken together, thrombopoietin levels are significantly higher in the sera of SLE patients than in healthy controls and anti-thrombopoietin antibodies are frequently found.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12043885     DOI: 10.1191/0961203302lu177oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

1.  Suspects in the tale of lupus-associated thrombocytopenia.

Authors:  P D Ziakas; J G Routsias; S Giannouli; A Tasidou; A G Tzioufas; M Voulgarelis
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 2.  Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review.

Authors:  Huaxia Yang; Huazhen Liu; Ziyue Zhou; Lidan Zhao; Yunyun Fei; Hua Chen; Fengchun Zhang; Xuan Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-07       Impact factor: 8.667

3.  The same genetic defect in three Tunisian families with Bernard Soulier syndrome: a probable founder Stop mutation in GPIbβ.

Authors:  Basma HadjKacem; Henda Elleuch; Ramzi Trigui; Jalel Gargouri; Ali Faouzi Gargouri
Journal:  Ann Hematol       Date:  2009-05-30       Impact factor: 3.673

4.  Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects.

Authors:  Vibha Jawa; Martha Hokom; Zheng Hu; Naglaa El-Abaadi; Yao Zhuang; Dietmar Berger; Shalini Gupta; Steven J Swanson; Narendra Chirmule
Journal:  Ann Hematol       Date:  2010-02-13       Impact factor: 3.673

Review 5.  Sjogren's syndrome complicating pancytopenia, cerebral hemorrhage, and damage in nervous system: A case report and literature review.

Authors:  Wenqing Yu; Wei Qu; Zhiyong Wang; Chunhong Xin; Rui Jing; Yinghui Shang; Huilin Zou; Hua Wang; Sizhou Feng
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

6.  A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes.

Authors:  Takuya Fukuda; Masahide Hamaguchi; Takafumi Osaka; Yoshitaka Hashimoto; Emi Ushigome; Mai Asano; Masahiro Yamazaki; Eriko Fukuda; Kei Yamaguchi; Koji Ogawa; Naoki Goshima; Michiaki Fukui
Journal:  Molecules       Date:  2020-04-04       Impact factor: 4.411

Review 7.  Lupus thrombocytopenia: pathogenesis and therapeutic implications.

Authors:  Nikolaos Galanopoulos; Anna Christoforidou; Zoe Bezirgiannidou
Journal:  Mediterr J Rheumatol       Date:  2017-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.